Pharmacognosy · Phytomedicine

Bacopa

Bacopa monnieri (L.) Pennell — An ancient Ayurvedic aquatic herb whose triterpenoid saponins (bacosides) deliver clinically validated cognitive enhancement, neuroprotection, and adaptogenic activity across multiple human randomised controlled trials.

40 Primary Refs
20+ Properties
Leaf Parts Used
Researched
Last Updated
Primary Source Wikiphyto · NCBI PubMed
Family Plantaginaceae

Taxonomy & Identification

A small aquatic perennial of tropical and subtropical wetlands, recognised in Ayurveda for over two millennia under the name Brahmi.

Kingdom
Plantae
Class
Magnoliopsida
Order
Lamiales
Family
Plantaginaceae (APG III)
Genus
Bacopa
Species
B. monnieri
Authority
(L.) Pennell
Synonyms
Lysimachia monnieri, Bramia monnieri, Herpestis monnieria
Evidence Grade B

Bacopa monnieri

A succulent, creeping aquatic herb of tropical origins, Bacopa monnieri has been classified within Plantaginaceae under the current APG III system, though it was formerly placed in Scrophulariaceae. Its genus encompasses more than 100 aquatic species distributed across the warm regions of the globe.

Common NamesBrahmi · Water Hyssop · Herb of Grace
SanskritSarasvati · Kapotavanka
HindiManduka Parni
Former FamilyScrophulariaceae

Description & Habitat

A glabrous, fleshy, creeping perennial that thrives in shallow water and wetland margins across tropical Asia, now naturalised in warm regions worldwide.

Morphology

A succulent, dicotyledonous, glabrous, frost-intolerant perennial well known to aquarium hobbyists. Leaves are succulent, thick and opposite; stems are slender, glabrous and green. The root system is fine, rough, small and branched, with a yellow-cream colouration.

Flowers & Fruit

Flowers are small and white, axillary and solitary, possessing five petals with slightly violet-tinged veins. The fruit is a glabrous ovoid capsule containing numerous seeds. Flowering occurs year-round in suitable tropical conditions.

Distribution & Ecology

Native to the warm, humid zones of the tropics: India, Nepal, Sri Lanka, China, Taiwan, Vietnam and the southern United States. It frequently colonises rice paddies and is sometimes considered a weed. It demonstrates tolerance to certain environmental pollutants through phytochelator production, including cadmium accumulation.[1]

History & Tradition

Documented in the Charaka Samhita, one of Ayurveda's foundational texts, Bacopa has been used for thousands of years as a nervine tonic and cognitive enhancer.

Ayurvedic Heritage

Bacopa is a cornerstone of the Ayurvedic pharmacopoeia, prominently referenced in the Charaka Samhita. It was traditionally indicated for disorders of the central nervous system — including nervous states, anxiety, attention deficits, and convulsions — as well as water retention, bronchitis, and joint pain. Remedies directed at the central nervous system in Ayurveda are often grouped under the name "Brahmi," a reference to Brahma, the creator god of the Hindu pantheon. Both Bacopa monnieri and Centella asiatica share this appellation.

Contemplative & Ritual Use

In India, Bacopa was traditionally used to enhance mental clarity during meditation, regarded as a plant that "illuminates the mind." This cultural association with spiritual cognition directly informed its modern study as a nootropic. The name Sarasvati, one of its Sanskrit designations, links the plant to the goddess of knowledge and learning — further underscoring its deep historical role as a cognitive and neurological herb in Vedic medicine.

Parts Used & Formulations

The leaf is the sole medicinally used part, processed as crude powder or as standardised extracts titrated to bacoside content.

Primary Part Used

Leaf — The aerial leaf tissue is the only part used therapeutically. Leaves are harvested from the whole plant and either dried to powder or subjected to ethanolic or aqueous extraction to concentrate the bacoside saponin fraction.

Available Galenical Forms

  • Crude powder — dried and milled leaf material
  • Standardised extract (5% bacosides) — the traditional standardisation level used in older clinical trials
  • High-potency standardised extract (20–55% bacosides) — used in more recent clinical trials (CDRI 08, Bacomind®)

Dosages

Dosages vary by preparation. Chronic administration over 90 days is required for full cognitive benefit; acute dosing shows partial effects.

Preparation Dose Frequency Duration Notes
Crude leaf powder 200 mg Once daily 90 days minimum Traditional Ayurvedic preparation; lower bacoside concentration
Standardised extract (5% bacosides) 300 mg Once daily 90 days minimum Used in elderly cognition RCT (Calabrese et al. 2008)[12]
CDRI 08 / high-potency extract 320–640 mg Once daily (acute) or chronic 90 days for chronic benefit; single dose for acute effect Used in multiple RCTs (Stough 2008, Downey 2013)[14][15]

Composition

The leaf is rich in triterpenoid saponins (bacosides), flavonoids, alkaloids, and sterols — all contributing to a broad spectrum of documented pharmacological activity.

Triterpenoid Saponins

Bacosides A & B The principal bioactive saponin fraction of B. monnieri; responsible for cognitive, anxiolytic, and neuroprotective effects. Their identities and analytical quantification have been extensively studied.[2][3]
Primary Active
Bacopasaponine C & Isomers Jujubogenin and pseudojujubogenin are structural isomers of bacopasaponine C; contribute to the overall saponin profile alongside hersaponin and monnierine.
Saponin
Betulinic acid, Wogonin, Oroxindine Additional triterpenoid and related compounds with complementary anti-inflammatory and neuroprotective properties.
Triterpene
Bacoside hydrolysis products Hydrolysis of bacosides yields glucose, arabinose, and bacogenins — the aglycone fraction that may directly interact with neuronal membranes.
Metabolite

Flavonoids, Alkaloids & Sterols

Luteolin & Apigenin The principal flavonoid constituents; luteolin contributes to the antimicrobial activity documented against Staphylococcus aureus.[31]
Flavonoid
Brahmine, Nicotinine, Herpestine, Hydrocotyline Minor alkaloid constituents contributing to the broader pharmacological profile; neurological activity under ongoing investigation.
Alkaloid
Cucurbitacins A class of tetracyclic triterpenoids also found in B. monnieri; identified by Bhandari et al.[4]
Triterpenoid
β-Sitosterol, Stigmasterol, Stigmastanol Phytosterols present alongside D-mannitol and micronutrients including calcium, phosphorus, iron, and ascorbic acid.
Sterol

Plant Properties

Evidence Grade B — Multiple Human RCTs & Meta-Analyses

Cognitive enhancement is the best-evidenced effect, supported by multiple double-blind RCTs, systematic reviews, and meta-analyses. Mechanistic evidence from animal and in vitro models supports all listed properties.

RCTs in Humans Meta-Analyses Animal Models In Vitro

Antioxidant & Anti-Stress

Bacopa modulates the stress response and reduces oxidative burden. Bacosides modulate Hsp70 expression and upregulate superoxide dismutase (SOD) and cytochrome P450 in rat brain tissue.[5] A double-blind crossover RCT confirmed reduction of multitasking stress reactivity and mood improvement.[6]

Cerebral Antioxidant

An extract standardised to 82% bacoside A significantly elevated concentrations of SOD, catalase (CAT), and glutathione peroxidase (GPX) in subcortical brain structures and the hippocampus of rats, demonstrating targeted neuroprotective antioxidant activity.[7]

Adaptogen

Classified as an adaptogen for its capacity to enhance the body's non-specific resistance to physiological and psychological stress, consistent with the Ayurvedic concept of a Rasayana (rejuvenating tonic). Acute administration at 320 mg and 640 mg confirmed adaptogenic effects in humans.[6]

Anti-Inflammatory (CNS)

Bacoside A inhibits the production of pro-inflammatory cytokines in the brain.[8] The plant extract also exerts anti-inflammatory effects on innate immune system cells in vitro,[38] with implications for chronic neuroinflammatory conditions.

Glutamate Modulation & GABA Enhancement

Bacopa reduces cerebral glutamate production — relevant to its anticonvulsant and neuroprotective activity[9] — while simultaneously increasing GABA (gamma-aminobutyric acid) levels in multiple brain regions and elevating serotonin concentrations.

Cognitive Enhancement

Chronic administration improves cognitive function in healthy young adults[10] and in individuals with attention deficit hyperactivity disorder and intellectual dysfunction.[11] A 90-day double-blind RCT confirmed nootropic effects in healthy subjects.[14]

Memory Enhancement

A systematic review of randomised controlled human clinical trials confirmed significant improvement in short- and long-term memory acquisition and retention.[18] Benefits extend to antioxidant activity in the cerebral cortex and hippocampus. Even a single acute dose demonstrates measurable effects.[15]

Serotonin System Upregulation

The ethanolic leaf extract of Bacopa monnieri upregulates expression of tryptophan hydroxylase (TPH2) and the serotonin transporter (SERT), with direct implications for improved learning and memory retention in animal models.[13]

Cognitive Enhancement in the Elderly

A randomised double-blind placebo-controlled trial in elderly subjects found that 300 mg of standardised extract daily significantly improved cognitive performance, anxiety, and depression scores versus placebo.[12]

Attention & Processing Speed

A meta-analysis of randomised controlled trials demonstrated significant improvements in cognition, attention, and information processing speed associated with standardised Bacopa extract use.[16][17]

Neuroplasticity & Dendritic Growth

Bacopa extract treatment enhances dendritic arborisation of hippocampal CA3 neurons in adult rats, providing a structural neuroplasticity mechanism that underpins long-term cognitive improvement.[19]

Synaptic Potentiation

Bacopa extract enhances learning-dependent hippocampal long-term synaptic potentiation, strengthening synaptic efficiency in hippocampal circuits essential for memory formation and consolidation.[20]

Neuroprotection

Demonstrates broad neuroprotective activity, including protection against aluminium-induced hippocampal toxicity in rats,[22] and prevention of alpha-synuclein aggregation relevant to Parkinson's disease pathology.[26]

Anti-Parkinsonian Activity

Bacopa has demonstrated potential in Parkinson's disease models via multiple mechanisms, including dopaminergic neuroprotection in Drosophila melanogaster[24] and inhibition of alpha-synuclein aggregation in Caenorhabditis elegans models.[26]

Anxiolytic

Bacoside A produces anxiolytic activity comparable to lorazepam (a benzodiazepine) in rodent models, crucially without the amnestic side effects characteristic of benzodiazepine class drugs — a significant differentiating feature.[27]

Antidepressant

Triterpene saponins from B. monnieri produce antidepressant effects in two standard murine models.[28] A standardised bacoside A extract showed antidepressant activity comparable to imipramine in rats,[30] alongside 5-HT2C receptor upregulation.[29]

Nitric Oxide Production

Bacopa increases nitric oxide (NO) production, with vasodilatory and potential neurotransmission-modulating implications. This mechanism may contribute to enhanced cerebral blood flow and the observed improvements in cognitive performance.

Antimicrobial

Both the extract of Bacopa monnieri and the flavonoid luteolin demonstrate significant antimicrobial activity against Staphylococcus aureus, with molecular docking studies confirming inhibitory interactions with pathogenic targets.[31]

Enzyme Inhibition (COMT, PEP, PARP)

A standardised Bacopa extract (Bacomind®) inhibits three enzymes associated with memory and learning disorders: catechol-O-methyltransferase (COMT), prolyl endopeptidase (PEP), and poly(ADP-ribose) polymerase (PARP) — elucidating part of the molecular basis for its nootropic effects.[39]

Phytoremediator

Beyond medicinal properties, B. monnieri demonstrates capacity for phytoremediation of contaminated water through phytochelator production, accumulating cadmium and modulating lipid peroxidation under heavy metal stress — a distinct ecotoxicological function.[1]

Clinical Indications

Indications for whole-plant phytotherapy, derived from clinical evidence and traditional Ayurvedic use. Bud and essential oil sections are not applicable to this species.

🧠
Cognitive & Neurological
Primary clinical domain — Grade B evidence
  • Memory disorders: A meta-analysis confirms significant improvement in cognition, attention, and information processing speed with standardised Bacopa extract.[32]
  • Mental and intellectual dysfunction: Indicated across multiple RCTs in healthy adults and populations with cognitive decline.
  • Attention deficit and hyperactivity disorders (ADHD): Evidence from clinical and mechanistic studies supports use in attention and concentration deficits.
  • Alzheimer's disease (investigational): Under active study; neuroprotective effects against beta-amyloid–induced cell death documented in vitro,[34] with cognitive and neuroprotective benefits in Alzheimer's animal models.[33] Multiple ethnobotanical reviews highlight its candidacy.[35][36][37]
  • Epilepsy: Neuroprotective role documented in epilepsy models, including modulation of glutamate receptor gene expression and hippocampal receptor activity.[9]
  • Parkinson's disease: Investigational; anti-Parkinsonian effects evidenced in multiple organism models.[23][24][25]
⚗️
Psychiatric & Systemic
Supportive evidence — Grade B / Preclinical
  • Anxiety: Anxiolytic effect comparable to lorazepam in animal models, without amnestic side effects.[27] Double-blind RCT confirmed stress-reactivity and mood improvement in humans.[6]
  • Depression: Antidepressant activity demonstrated in rodent models, with effects comparable to imipramine at equivalent doses.[30][28]
  • Chronic systemic and cerebral inflammatory conditions: Relevant in conditions linked to the innate immune system, given documented inhibition of CNS pro-inflammatory cytokine pathways.[38]
  • Stress and burnout: Adaptogenic effects at acute doses support use in stress management protocols; reduction of cortisol-related markers evidenced in animal models.[5]

Mode of Action

Bacopa's effects arise from a multi-target pharmacodynamic profile, acting simultaneously on neurotransmitter systems, antioxidant pathways, neuroplasticity signalling, and enzyme inhibition.

🔬

Enzyme Inhibition

Standardised Bacopa extract inhibits COMT (catechol-O-methyltransferase), PEP (prolyl endopeptidase), and PARP (poly-ADP-ribose polymerase) — three enzymes linked to impaired memory and learning. Inhibition of COMT prolongs dopaminergic and adrenergic signalling; PEP inhibition reduces neuropeptide degradation; PARP inhibition limits neuronal apoptosis.[39]

Monoamine & Neurotransmitter Modulation

Bacopa upregulates tryptophan hydroxylase (TPH2) and the serotonin transporter (SERT), increasing serotonergic tone — a mechanism directly linked to improved memory retention.[13] Simultaneously, it reduces glutamate excitotoxicity[9] and increases GABA concentrations across multiple brain regions, explaining anxiolytic and anticonvulsant effects.

🛡️

Antioxidant Cascade Activation

Bacosides directly activate the antioxidant defence system in the hippocampus and subcortical structures, elevating SOD, CAT, and GPX — three key antioxidant enzymes — thereby neutralising reactive oxygen species (ROS) implicated in neurodegeneration and cognitive decline.[7]

🌿

Neuroplasticity Enhancement

Bacopa promotes dendritic branching and growth of hippocampal CA3 neurons,[19] structurally strengthening the memory-forming circuits of the brain. This is complemented by enhancement of hippocampal long-term synaptic potentiation (LTP),[20] the cellular mechanism underpinning learning and memory consolidation.

🔥

Neuroinflammation Suppression

Bacoside A inhibits the production of pro-inflammatory cytokines in the brain,[8] while whole-plant extract suppresses inflammatory pathways in innate immune cells in vitro.[38] This dual central and peripheral anti-inflammatory activity addresses the neuroinflammatory component common to Alzheimer's disease, depression, and age-related cognitive decline.

🔗

Alpha-Synuclein & Amyloid Pathway Modulation

In Parkinson's models, Bacopa limits alpha-synuclein aggregation — the principal pathological hallmark of the disease — in transgenic C. elegans.[26] In Alzheimer's models, it protects primary cortical neurons against beta-amyloid–induced cell death[34] and enhances cognitive performance in Alzheimer's animal models.[33]

Safety & Precautions

Bacopa monnieri has an established safety profile in animal toxicology studies. Human clinical experience identifies mild GI effects as the most common adverse event.

⚠️

Adverse Effects & Toxicity

  • Gastrointestinal effects: Nausea, dry mouth, and fatigue are the most commonly reported adverse events in human trials; typically mild and dose-dependent. Taking the extract with food generally mitigates GI symptoms.
  • No acute or chronic toxicity in animal models: A rigorous acute and chronic toxicity study in Sprague-Dawley rats found no toxicological signals at standard doses.[40]
  • Hyperthyroidism risk: Avoid in individuals with hyperthyroidism; Bacopa may further stimulate thyroid hormone levels.
🚫

Contraindications & Drug Interactions

  • Pregnancy and lactation: Avoid use during pregnancy and breastfeeding due to insufficient safety data.
  • Antipsychotic interactions: Clinically documented pharmacological interaction with neuroleptics; specifically, Bacopa potentiates the effects of phenothiazines (first-generation antipsychotics). Concurrent use should be avoided.
  • Hyperthyroidism: Contraindicated in individuals with known hyperthyroidism.
  • Sedative medications: Given Bacopa's GABAergic and serotonergic activity, caution is warranted with concurrent benzodiazepines, SSRIs, or other CNS-active agents, though direct clinical interaction data in humans are limited.
Clinical Disclaimer: This monograph is for educational and professional reference only. It does not constitute medical advice, diagnosis, or treatment guidance. Bacopa monnieri preparations should be used under the supervision of a qualified healthcare provider. The Health Reference reviews content against current primary literature.

Frequently Asked Questions

What is Bacopa monnieri used for clinically?
Bacopa monnieri is primarily indicated for cognitive enhancement, memory improvement, and attention support. Multiple randomised controlled trials and meta-analyses confirm significant improvements in memory acquisition, information processing speed, and attention in healthy adults, older populations, and individuals with cognitive dysfunction. It is also studied for anxiety reduction, depression, epilepsy, and as a neuroprotective agent in Parkinson's and Alzheimer's disease models.
What are bacosides and why are they the key active compounds?
Bacosides are the principal triterpenoid saponins of Bacopa monnieri — specifically bacoside A and bacoside B — found predominantly in the leaf. They are responsible for the herb's cognitive, neuroprotective, anxiolytic, and antidepressant effects. Standardised extracts are titrated to ensure consistent bacoside content (historically 5%, and in more recent clinical preparations 20–55%), allowing reproducible clinical dosing and reliable outcome measurement across trials.
How long does Bacopa take to produce cognitive benefits?
Research shows cognitive benefits from both acute and chronic administration. The most robust and sustained improvements — particularly in memory formation and retention — emerge after 90 days of daily supplementation with a standardised extract. Several trials also document measurable improvements in cognitive performance following a single acute dose of 320–640 mg (CDRI 08 extract), though chronic use delivers more comprehensive and lasting effects.
Is Bacopa monnieri safe for long-term use?
The available evidence supports a favourable long-term safety profile. Animal studies demonstrate no acute or chronic toxicity at standard therapeutic doses. The most common adverse effects in human trials are mild gastrointestinal symptoms (nausea, dry mouth), which are minimised by taking the extract with food. Bacopa should be avoided during pregnancy and breastfeeding, in the presence of hyperthyroidism, and its combination with antipsychotic medications (especially phenothiazines) requires clinical supervision.
Does Bacopa cause memory loss or amnesia like benzodiazepines?
No. This is a clinically significant distinguishing feature. Bacoside A produces anxiolytic effects comparable in magnitude to lorazepam (a benzodiazepine) in rodent models, but crucially without the amnestic side effects typical of benzodiazepine pharmacology. This is consistent with Bacopa's primary mechanism of action being enhancement of synaptic plasticity and neurotransmitter function, rather than broad GABA-A receptor potentiation as seen with benzodiazepines.
What is the difference between Brahmi as Bacopa and Brahmi as Centella asiatica?
Both Bacopa monnieri and Centella asiatica (Gotu Kola) share the traditional Sanskrit/Ayurvedic name "Brahmi," which reflects their shared indication as CNS-active nervine tonics in Vedic medicine. In southern India, "Brahmi" typically refers to Bacopa monnieri, whereas in northern India it may refer to Centella asiatica. They are botanically distinct plants from different families, with different phytochemical profiles (bacosides vs. asiaticoside/madecassoside), and should not be substituted for one another without clinical guidance.

Bibliography

1. Singh S, Eapen S, D'Souza SF. Cadmium accumulation and its influence on lipid peroxidation and antioxidative system in an aquatic plant, Bacopa monnieri L. Chemosphere. 2006;62(2):233–46. PubMed PMID:15993469 →
2. Deepak M, Amit A. The need for establishing identities of "bacoside A and B", the putative major bioactive saponins of Indian medicinal plant Bacopa monnieri. Phytomedicine. 2004;11(2–3):264–8. PubMed PMID:15070183 →
3. Deepak M, Sangli GK, Arun PC, Amit A. Quantitative determination of the major saponin mixture bacoside A in Bacopa monnieri by HPLC. Phytochem Anal. 2005;16(1):24–9. PubMed PMID:15688952 →
4. Bhandari P, Kumar N, Singh B, Kaul VK. Cucurbitacins from Bacopa monnieri. Phytochemistry. 2007;68(9):1248–54. PubMed PMID:17442350 →
5. Chowdhuri DK, Parmar D, Kakkar P et al. Antistress effects of bacosides of Bacopa monnieri: modulation of Hsp70 expression, superoxide dismutase and cytochrome P450 activity in rat brain. Phytother Res. 2002;16(7):639–45. PubMed PMID:12410544 →
6. Benson S, Downey LA, Stough C et al. An acute, double-blind, placebo-controlled cross-over study of 320 mg and 640 mg doses of Bacopa monnieri (CDRI 08) on multitasking stress reactivity and mood. Phytother Res. 2014;28(4):551–9. PubMed PMID:23788517 →
7. Bhattacharya SK, Bhattacharya A, Kumar A, Ghosal S. Antioxidant activity of Bacopa monniera in rat frontal cortex, striatum and hippocampus. Phytother Res. 2000;14(3):174–9. PubMed PMID:10815010 →
8. Nemetchek MD, Stierle AA, Stierle DB, Lurie DI. The Ayurvedic plant Bacopa monnieri inhibits inflammatory pathways in the brain. J Ethnopharmacol. 2017;197:92–100. PubMed PMID:27473605 →
9. Paulose CS, Chathu F, Khan SR, Krishnakumar A. Neuroprotective role of Bacopa monnieri extract in epilepsy and effect of glucose supplementation during hypoxia: glutamate receptor gene expression. Neurochem Res. 2008;33(9):1663–71. PubMed PMID:17940877 →
10. Roodenrys S, Booth D, Bulzomi S et al. Chronic effects of Brahmi (Bacopa monnieri) on human memory. Neuropsychopharmacology. 2002;27(2):279–81. PubMed PMID:12093601 →
11. Clinical evidence on Bacopa for cognitive dysfunction and ADHD populations. Bacopin Clinical Data →
12. Calabrese C, Gregory WL, Leo M et al. Effects of a standardized Bacopa monnieri extract on cognitive performance, anxiety, and depression in the elderly: a randomized, double-blind, placebo-controlled trial. J Altern Complement Med. 2008;14(6):707–13. PubMed PMID:18611150 →
13. Charles PD, Ambigapathy G, Geraldine P et al. Bacopa monniera leaf extract up-regulates tryptophan hydroxylase (TPH2) and serotonin transporter (SERT) expression: implications in memory formation. J Ethnopharmacol. 2011;134(1):55–61. PMID:21129470.
14. Stough C, Downey LA, Lloyd J et al. Examining the nootropic effects of a special extract of Bacopa monniera on human cognitive functioning: 90 day double-blind placebo-controlled randomized trial. Phytother Res. 2008;22(12):1629–34. PubMed PMID:18683852 →
15. Downey LA, Kean J, Nemeh F et al. An acute, double-blind, placebo-controlled crossover study of 320 mg and 640 mg doses of a special extract of Bacopa monnieri (CDRI 08) on sustained cognitive performance. Phytother Res. 2013;27(9):1407–13. PubMed PMID:23281132 →
16. Kongkeaw C, Dilokthornsakul P, Thanarangsarit P et al. Meta-analysis of randomized controlled trials on cognitive effects of Bacopa monnieri extract. J Ethnopharmacol. 2014;151(1):528–35. PubMed PMID:24252493 →
17. Stough C, Lloyd J, Clarke J et al. The chronic effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy human subjects. Psychopharmacology. 2001;156(4):481–484. DOI → PubMed PMID:11498727 →
18. Pase MP, Kean J, Sarris J et al. The cognitive-enhancing effects of Bacopa monnieri: a systematic review of randomized, controlled human clinical trials. J Altern Complement Med. 2012;18(7):647–52. PubMed PMID:22747190 →
19. Vollala VR, Upadhya S, Nayak S. Enhanced dendritic arborization of hippocampal CA3 neurons by Bacopa monniera extract treatment in adult rats. Rom J Morphol Embryol. 2011;52(3):879–86. PubMed PMID:21892534 →
20. Promsuban C, Limsuvan S, Akarasereenont P et al. Bacopa monnieri extract enhances learning-dependent hippocampal long-term synaptic potentiation. Neuroreport. 2017;28(16):1031–1035. PubMed PMID:28885486 →
21. Roy Supriya & Awasthi Himani. Herbal medicines as neuroprotective agent: a mechanistic approach. Int J Pharmacy Pharmaceutical Sci. 2017;9(11):1–7. Full Text →
22. Nannepaga JS, Korivi M, Tirumanyam M et al. Neuroprotective effects of Bacopa monniera whole-plant extract against aluminum-induced hippocampus damage in rats. Chin J Physiol. 2014;57(5):279–85. PubMed PMID:25241988 →
23. Gourie-Devi M, Ramu MG, Venkataram BS. Treatment of Parkinson's disease in Ayurveda (ancient Indian system of medicine): discussion paper. J R Soc Med. 1991;84(8):491–492. PMC Full Text →
24. Jansen RL, Brogan B, Whitworth AJ, Okello EJ. Effects of five Ayurvedic herbs on locomotor behaviour in a Drosophila melanogaster Parkinson's disease model. Phytother Res. 2014;28(12):1789–95. PubMed PMID:25091506 →
25. Aguiar S, Borowski T. Neuropharmacological Review of the Nootropic Herb Bacopa monnieri. Rejuvenation Research. 2013;16(4):313–326. PMC Full Text →
26. Jadiya P, Khan A, Sammi SR et al. Anti-Parkinsonian effects of Bacopa monnieri: insights from transgenic and pharmacological Caenorhabditis elegans models of Parkinson's disease. Biochem Biophys Res Commun. 2011;413(4):605–10. PubMed PMID:21925152 →
27. Bhattacharya SK, Ghosal S. Anxiolytic activity of a standardized extract of Bacopa monniera: an experimental study. Phytomedicine. 1998;5(2):77–82. PubMed PMID:23195757 →
28. Zhou Y, Shen YH, Zhang C et al. Triterpene saponins from Bacopa monnieri and their antidepressant effects in two mice models. J Nat Prod. 2007;70(4):652–5. PubMed PMID:17343408 →
29. Krishnakumar A, Nandhu MS, Paulose CS. Upregulation of 5-HT2C receptors in hippocampus of pilocarpine-induced epileptic rats: antagonism by Bacopa monnieri. Epilepsy Behav. 2009;16:225–230. PubMed PMID:19700373 →
30. Sairam K, Dorababu M, Goel RK, Bhattacharya SK. Antidepressant activity of standardized extract of Bacopa monniera in experimental models of depression in rats. Phytomedicine. 2002;9(3):207–11. PubMed PMID:12046860 →
31. Emran TB, Rahman MA, Uddin MMN et al. Molecular docking and inhibition studies on the interactions of Bacopa monnieri's potent phytochemicals against pathogenic Staphylococcus aureus. DARU J Pharm Sci. 2015;23(1):26. PubMed PMID:25884228 →
32. Kongkeaw C, Dilokthornsakul P, Thanarangsarit P et al. Meta-analysis of randomized controlled trials on cognitive effects of Bacopa monnieri extract. J Ethnopharmacol. 2014;151(1):528–35. PubMed PMID:24252493 →
33. Uabundit N, Wattanathorn J, Mucimapura S, Ingkaninan K. Cognitive enhancement and neuroprotective effects of Bacopa monnieri in Alzheimer's disease model. J Ethnopharmacol. 2010;127(1):26–31. PubMed PMID:19808086 →
34. Limpeanchob N, Jaipan S, Rattanakaruna S et al. Neuroprotective effect of Bacopa monnieri on beta-amyloid-induced cell death in primary cortical culture. J Ethnopharmacol. 2008;120(1):112–7. PubMed PMID:18755259 →
35. Howes MJ, Houghton PJ. Ethnobotanical treatment strategies against Alzheimer's disease. Curr Alzheimer Res. 2012;9(1):67–85. PubMed PMID:22329652 →
36. Eckert GP. Traditional used Plants against Cognitive Decline and Alzheimer Disease. Front Pharmacol. 2010;1:138. PubMed PMID:21833177 →
37. Chaudhari KS, Tiwari NR, Tiwari RR, Sharma RS. Neurocognitive Effect of Nootropic Drug Brahmi (Bacopa monnieri) in Alzheimer's Disease. Annals of Neurosciences. 2017;24(2):111–122. PMC Full Text →
38. Williams R, Münch G, Gyengesi E, Bennett L. Bacopa monnieri (L.) exerts anti-inflammatory effects on cells of the innate immune system in vitro. Food Funct. 2014;5(3):517–20. PubMed PMID:24452710 →
39. Dethe S, Deepak M, Agarwal A. Elucidation of Molecular Mechanism(s) of Cognition Enhancing Activity of Bacomind®: A Standardized Extract of Bacopa Monnieri. Pharmacogn Mag. 2016;12(Suppl 4):S482–S487. PubMed PMID:27761079 →
40. Sireeratawong S, Jaijoy K, Khonsung P et al. Acute and chronic toxicities of Bacopa monnieri extract in Sprague-Dawley rats. BMC Complement Altern Med. 2016;16:249. Abstract →

Additional Clinical & Reference Literature

Pothier J. La bacopa ou hysope d'eau, une plante adaptogène issue de la médecine ayurvédique. Phytothérapie européenne. N°53, Nov–Dec 2009.
Patwardhan B, Warude D, Pushpangadan P, Bhatt N. Ayurveda and traditional Chinese medicine: a comparative overview. Evid Based Complement Alternat Med. 2005;2(4):465–73. PubMed PMID:16322803 →
Katoch M, Singh G, Sharma S et al. Cytotoxic and antimicrobial activities of endophytic fungi isolated from Bacopa monnieri (L.) Pennell. BMC Complement Altern Med. 2014;14:52. Abstract →
Al-Snafi AE. The pharmacology of Bacopa monniera. A review. Int J Pharma Sciences Research. 2013;4(12):154–159. Full Text →